Intervention Review

You have free access to this content

Selective serotonin reuptake inhibitors for premenstrual syndrome

  1. Jane Marjoribanks1,
  2. Julie Brown1,*,
  3. Patrick Michael Shaughn O'Brien2,
  4. Katrina Wyatt3

Editorial Group: Cochrane Gynaecology and Fertility Group

Published Online: 7 JUN 2013

Assessed as up-to-date: 11 FEB 2013

DOI: 10.1002/14651858.CD001396.pub3


How to Cite

Marjoribanks J, Brown J, O'Brien PMS, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD001396. DOI: 10.1002/14651858.CD001396.pub3.

Author Information

  1. 1

    University of Auckland, Obstetrics and Gynaecology, Auckland, New Zealand

  2. 2

    Keele University Medical School, Academic Department of Obstetrics and Gynaecology, Stoke-on-Trent, Staffordshire, UK

  3. 3

    Peninsula College of Medicine and Dentistry, Institute of Health Service Research, Exeter, UK

*Julie Brown, Obstetrics and Gynaecology, University of Auckland, Park Rd, Grafton, Auckland, 1003, New Zealand. j.brown@auckland.ac.nz.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 7 JUN 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Arrendondo 1997 {published data only}
  • Arredondo-Soberon F, Freeman EW, Sondheimer SJ. Relationship and response of food cravings and depression to sertraline in patients with premenstrual syndrome. Fertility and Sterility 1997;October:S28.
Cohen 2002 {published data only}
  • Cohen L, Miner C, Brown E, Dillon J. Efficacy of intermittent fluoxetine dosing in premenstrual dysphoric disorder (PMDD). European Neuropsychopharmacology 2001;11 Suppl 3:210.
  • Cohen L, Miner C, Brown E, Freeman E, Halbreich U, Sundell K, McCray S. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo controlled, clinical trial using computerized diaries. Obstetrics and Gynecology 2002;100(3):435-44.
  • Cohen L, Soares C, Yonkers K, et al. Paroxetine controlled release (CR) is effective in the treatment of premenstrual dysphoric disorder (PMDD): Results from a randomized placebo controlled trial. 15th Annual US Psychiatric and Mental Health Congress. October 28- November 3rd. Las Vegas, Nevada. 2002:Abstract 39.
  • Judge R, Brown E, Miner C, Dillon J. Intermittent fluoxetine dosing in premenstrual dysphoric syndrome. World Journal of Biological Psychiatry 2001;2 Suppl:204.
  • Miner C, Cohen LS, O'Brien PMS, Davis S, Brown E, Jacobson J. Predictors of response to luteal phase fluoxetine treatment of PMDD. The International Journal of Neuropsychopharmacology 2002;5 Suppl:87.
Cohen 2004 {published data only}
  • Cohen L, Soares C, Yonkers K, Bellew K, Bridges I, Heller V. Paroxetine controlled release is effective in treating premenstrual dysphoric disorder. Obstetrics and Gynecology 2003;101 Suppl 4:111.
  • Cohen L, Soares C, Yonkers K, Bellew K, Bridges I, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: A double blind, placebo controlled trial. Psychosomatic Medicine 2004;66:707-13.
  • GlaxoSmithKline. A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F677&studyId=3742A8A5-2C3C-4A40-B9B5-7975DF70CF53&compound=paroxetine Accessed 16 August 2012.
  • GlaxoSmithKline NZ. Phone call from a representative of GlaxoSmithKline New Zealand (in response to an email sent by J Marjoribanks) confirming that 29060/677 (Cohen 2004) and 29060/689 (Pearlstein 2005) were separate studies July 2012.
  • Pearlstein 2012. Email to Jane Marjoribanks from Teri Pearlstein advising that participants in Pearlstein 2005 and Cohen 2004 did not, to her knowledge, overlap. 22.6.12.
Crnobaric 1998 {published data only}
  • Crnobaric C, Jasovic-Gasic M, Milanovanic S, Miljevic C. Treatment of premenstrual dysphoric disorder with fluoxetine during the luteal phase. 9th Congress of the Association of European Psychiatrists. Copenhagen, Denmark, 20-24 September 1998.
Eriksson 1995 {published data only}
  • Eriksson E, Hedberg MA, Andersch B, Sunblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76.
Eriksson 2008 {published data only}
  • Eriksson E, Ekman A, Sinclair S, Sorvik K, Ysandeer C, Mattson U-B, Nissbrandt H. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology 2008;28(2):195-202.
Freeman 1999 {published data only}
Freeman 2004 {published data only}
  • Freeman E, Rickels K, Sondheimer S, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. American Journal of Psychiatry 2004;161(2):343-51.
  • Freeman EW, Rickels K, Sammel MD, Lin H, Sondheimer SS. Time to relapse after short-term or long-term sertraline treatment for severe premenstrual syndromes. Archives of General Psychiatry 2009;66(5):537-44.
Freeman 2010 {unpublished data only}
  • Freeman E. Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study NCT00523705. http://clinicaltrials.gov/ct2/show/NCT00523705.
Glaxo 1996 {unpublished data only}
  • GlaxoSmithKline. A Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety and Tolerability of Paroxetine in Patients with Premenstrual Dysphoric Disorder. [Study No PAR 29060.400]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F400&studyId=80268FE4-8DB0-4A5A-8CF4-51162DA5EE83&compound=paroxetine Accessed 16 August 2012.
Glaxo 1996a {unpublished data only}
  • GlaxoSmithKline. A Multicentre, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Paroxetine (5mg OD Vs 10mg OD Vs 20mg OD) in Patients with Premenstrual Dysphoric Disorder (PMDD) [Study No PAR 29060.427]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F427&studyId=46B83DBA-A3AD-44FB-84F7-51BC66679F35&compound=paroxetine Accessed 16 August 2012.
Glaxo 2001 {unpublished data only}
  • GlaxoSmithKline. A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder [Study No 29060/688]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F688&studyId=4EAE38F8-954D-453B-BA8C-32CA4FFAD277&compound=paroxetine Accessed 16 August 2012.
Halbreich 1997 {published data only}
Halbreich 2002 {published data only}
  • Halbreich U, Bergeron R, Freeman E, Stout A, Cohen L. Intermittent (luteal phase) dosing of sertraline effective in PMDD. International Journal of Neuropsychopharmacology 2000;3 Suppl 1:248.
  • Halbreich U, Bergeron R, Stout A, Freeman E, Yonkers K, Pearlstein T, et al. Dosing of sertraline is effective in premenstrual dysphoric disorder. 155th Annual Meeting of the American Psychiatric Association. 13th-18th May 2000.
  • Halbreich U, Bergeron R, Yonkers K, Freeman E, Stout A, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology 2002;100(6):1219-29.
  • Pearlstein T, Yonkers K, Fayyad R, Gillespie J. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of Affective Disorders 2005;85:275-82.
Jermain 1999 {published data only}
Kornstein 2006 {published data only}
  • Kornstein S, Gillespie J. Double blind placebo controlled study of sertraline in premenstrual syndrome. 155th Annual Meeting of the American Psychiatric Association. May 18-23, Philadelphia PA. 2002:NR248.
  • Kornstein S, Pearlstein T, Fayyad R, Farfel G, Gillespie J. Low dose sertraline in the treatment of moderate to severe premenstrual syndrome: Efficacy of 3 dosing strategies. Journal of Clinical Psychiatry 2006;67(10):1624-32.
Landen 2007 {published data only}
  • Bellew KM, Landen M, Hunter B, McCafferty JP. Social functioning improves with paroxetine treatment. 155th Annual Meeting of the American Psychiatric Association. May 18-23, Philadelphia. 2002:NR282.
  • GlaxoSmithKline. A Placebo-Controlled Study to Investigate the Efficacy of Intermittent and Continuous Treatment With Paroxetine in Patients With Premenstrual Dysphoric Disorder (PMDD). http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F658&studyId=186F6412-CDE1-4505-8ACD-FBB1858393EB&compound=paroxetine Accessed 16 August 2012.
  • Landen M, Sorvik K, Ysander C, Allgulander C, Nissbrandt H, Gezelius B, et al. A placebo controlled trial exploring the efficacy of paroxetine for the treatment of premenstrual dysphoria. American Psychiatric Association, 155th annual meeting. May 18-23. Philadelphia, PA., 2002.
  • Landen M, Ysander K, Sorvik K, Nissbrandt H, Allgulander C, Hunter B, et al. A placebo controlled study of the efficacy of intermittent and continuous treatment with paroxetine for premenstrual dysphoric disorder (PMDD). European Neuropsychopharmacology 2001;11 Suppl 3:308-9.
  • Landen MSG. A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria. http://clinicaltrials.gov/ct2/show/NCT00516113 2007.
  • Länden M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E. Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153-61.
Menkes 1992 {published data only}
Miner 2002 {published data only}
  • Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal phase dosing with enteric coated fluoxetine 90mg in premenstrual dysphoric disorder: A randomised, double blind, placebo controlled clinical study. Clinical Therapeutics 2002;24(3):417-33.
  • Miner C, Cohen LS, O'Brien PMS, Davis S, Brown E, Jacobson J. Predictors of response to luteal phase fluoxetine treatment of PMDD. The International Journal of Neuropsychopharmacology 2002;5 Suppl:87.
Ozeren 1997 {published data only}
Pearlstein 1997 {published data only}
  • Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dsyphoric disorder. Journal of Clinical Psychopharmacology 1997;17:261-6.
Pearlstein 2005 {published data only}
  • GlaxoSmithKline. A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F689&studyId=6F9A5C75-99C3-4F11-AED7-A122263D1746&compound=paroxetine Accessed 16 August 2012.
  • GlaxoSmithKline NZ. Phone call from a representative of GlaxoSmithKline New Zealand (in response to an email sent by J. Marjoribanks) confirming that 29060/677 (Cohen 2004) and 29060/689 (Pearlstein 2005) were separate studies July 2012.
  • Pearlstein 2012. Email to Jane Marjoribanks from Teri Pearlstein advising that participants in Pearlstein 2005 and Cohen 2004 did not, to her knowledge, overlap. 22.6.12.
  • Pearlstein T, Bellew K, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double blind, placebo controlled trial. 41st Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico. Dec 8-12 2002.
Steiner 1995 {published data only}
  • Dillon J, Steiner M, Judge R, Brown E. Fluoxetine improves social functioning in women with premenstrual dysphoria. International Journal of Gynecology and Obstetrics 2000;70 Suppl 3:99.
  • Koke S, Steiner M, Judge R, Babcock S, Dillon J. Efficacy of fluoxetine in improving mood symptoms and social impairments in patients with PMDD. Psychosomatics 2001;42(2):178.
  • Nilsson M Judge R, Brown E, Schuler C. Fluoxetine's efficacy in improving mood. physical and social impairment symptoms associated with PMDD. International Journal of Gynecology and Obstetrics 2000;Abstract Book 3:96.
  • Steiner M, Babcock S, McCray SD, Romano S. Fluoxetine's efficacy in improving premenstrual dysphoric disorder. 152nd Annual Meeting of the American Psychiatric Association, Washington DC. USA. 15-20th May 1999.
  • Steiner M, Babcock S, Steinberg SI, Stewart DE, Carter D, Berger C. Fluoxetine's efficacy in improving physical symptoms associated with pdd: results from a multisite, randomized placebo controlled trial. 152nd Annual Meeting of the American Psychiatric Association. Washington DC USA. 15-20 May 1999.
  • Steiner M, Brown E, Trzepacz P, Dillon J, Berger C, Carter D, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Archives of Women's Mental Health 2003;6:71-7.
  • Steiner M, Judge R, Brown E, Dillon J. Fluoxetine improves social functioning in women with premenstrual dysphoric disorder (PMDD). International Journal of Neuropsychopharmacology. 2000; Vol. 3, issue suppl1:247.
  • Steiner M, Judge R, Brown E, Dillon J. Fluoxetine's effect on food craving during the luteal phase in women with premenstrual dysphoric disorder (PMDD). International Journal of Gynecology and Obstetrics 2000;70(4):D147.
  • Steiner M, Romano S, Babcock S. Fluoxetine's efficacy in improving physical symptoms associated with PMDD. Journal of the European College of Neuropsychopharmacology 1999;9 Suppl 5:208.
  • Steiner M, Romano S, Babcock S. Fluoxetine's efficacy in improving physical symptoms associated with PMDD. Journal of the European College of Neuropsychopharmacology 2001;Suppl:208.
  • Steiner M, Romano S, Babcock, Dillon J, Shuler C, Berger C, et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. British Journal of Obstetrics and Gynaecology 2001;108:462-8.
  • Steiner M, Romano SJ, Babcock S, McCray S, Dillon JA. Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD. Journal of the European College of Neuropsychopharmacology 2001;Suppl:208.
  • Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoric disorder. The New England Journal of Medicine 1995;332:1529-34.
  • Steiner M, Trezepacz PT, Brown E. Premenstrual dysphoric disorder (PMDD) and work efficiency: Response to fluoxetine in a randomized clinical trial. European Neuropsychopharmacology 2000;10(3):226-7.
  • Steiner M, Trzepacz PT, Brown E. Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial. Journal of European College of Neuropsychopharmacology 2001;Suppl:226.
  • Trzepacz PT, Steiner M, Brown E. Premenstrual dysphoric disorder and work efficiency: Response to fluoxetine in a randomized clinical trial. Psychosomatics 2001;42(2):184.
  • Trzepacz PT, Steiner M, Brown E, Dillon J. Premenstrual dysphoric disorder and work efficiency: Response to fluoxetine in a randomized clinical trial. World Journal of Biological Psychiatry 2001;2 Suppl:340S.
Steiner 2005 {published data only}
  • Gee M, Bellew K, Holland F, Van Erp E, Perera P, McCafferty J. Luteal phase dosing of paroxetine controlled release is effective in treating PMDD. 156th Annual Meeting American Psychiatric Association, May 17-22 San Francisco, CA. 2003:NR760.
  • GlaxoSmithKline. A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder [Study No 29060/717]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F717&studyId=CA9A3538-05F2-43D8-A1E2-342281DDD178&compound=paroxetine Accessed 16 August 2012.
  • Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van Erp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology 2005;193:352-60.
Steiner 2008 {published data only}
  • GlaxoSmithKline. A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg/day and 20mg/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F621&studyId=8696C1BE-93D7-4883-AD54-2BC6CF7740BB&compound=paroxetine Accessed 16 August 2012.
  • Hamilton Health Sciences Corporation. Luteal Phase Administration of Paroxetine for the Treatment of PMDD: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women NCT00620581. http://clinicaltrials.gov/ct2/show/NCT00620581 2008.
  • Steiner M, Ravindran AV, LeMedello J-M, Carter D, Huang JO, Anonychuk AM, Simpson SD. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. Journal of Clinical Psychiatry 2008;69:991-8.
Stone 1991 {published data only}
Su 1997 {published data only}
Wikander 1998 {published data only}
  • Wikander I, Sunblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?. Journal of Clinical Psychopharmacology 1998;18:390-8.
Wood 1992 {published data only}
  • Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstetrics and Gynecology 1992;80:339-44.
Yonkers 1997 {published data only}
Young 1998 {published data only}
  • Young SA, Hurt PH, Benedeck DM, Howard RS. Treatment of PDD with sertraline during the luteal phase: a randomised, double-blind, placebo controlled crossover trial. Journal of Clinical Psychiatry 1998;59:76-80.
  • Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double blind placebo controlled crossover trial. American Psychiatric Association 150th Annual Meeting, San Diego USA. 1997.
  • Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double blind placebo controlled crossover trial. Journal of Clinical Psychiatry 1998;59:76-80.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Alpay 2001 {published data only}
  • Alpay F, Turhan N. Intermittant versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders. International Journal of Fertility 2001;46:228-31.
Brandenburg 1993 {published data only}
De la Gandara 1997 {published data only}
  • De La Gandara Martin JJ. Trastorno disforico premenstrual: Tratamiento a largo plazo con fluoxetina y discontinuacion [Premenstrual dysphoric disorder:long term treatment with fluoxetine and discontinuation]. Actas Luso-Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1997;25:235-42.
Diegoli 1998 {published data only}
  • Diegoli M, DaFonseca A, Diegoli CA, Pinotti JA. A double blind trial of four medications to treat severe premenstrual syndrome. International Journal of Gynecology and Obstetrics 1998;62:63-7.
Elks 1993 {published data only}
Flores Ramos 2003 {published data only}
  • Fores Ramos M, Ontiveros Uribe M, Cortes Sotres J. Comparison between continuous and intermittent treatment with citalopram..... [Comparacion entre el tratamiento continuo y el intermitente con citalopram para el trastorno disforico premenstrual]. Salud Mental 2003;26(003):37-45.
Freeman 1996 {published data only}
  • Freeman EW, Rickels K, Sondheimer SJ. Comparison of serotonergic and noradrenergic antidepressant medications in treatment of premenstrual syndrome (PMS). XXIst Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland. 12-16th July 1998.
  • Freeman EW, Rickels K, Sondheimer SJ. Sertraline versus desipramine in PMS treatment. 151st Annual Meeting of the American Psychiatric Association, Toronto, Canada. 30th May-4th June 1998, issue 118C.
  • Freeman EW, Rickels K, Sondheimer SJ, Wittmaack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: an open label trial. Journal of Clinical Psychiatry 1996;57:7-11.
Freeman 1999b {published data only}
  • Freeman EW, Rickels K, Arredono F, Lee-Chuan K, Pollack S, Sondheimer S. Full or half cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. Journal of Cliniical Psychopharmacology 1999;19(1):3-9.
Freeman 2000 {published data only}
  • Freeman EW, Sondheimer SJ, Polansky M, Garcia-Espagna B. Predictors of response to sertraline treatment of severe premenstrual syndromes. Journal of Clinical Psychiatry 2000;61(8):579-84.
Freeman 2002 {published data only}
  • Freeman E, Jabara S, Sondheimer S, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study. Journal of Womens Health & Gender-based Medicine 2002;11(5):459-64.
Freeman 2005 {published data only}
  • Freeman E, Sondheimer S, Sammel M, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. Journal of Clinical Psychiatry 2005;66(6):769-73.
Glaxo 2002 {unpublished data only}
  • GlaxoSmithKline. A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689 [Study no 29060/711]. http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=29060%2F711&studyId=4A384A1A-46F7-4E8B-915B-4B324BB64491&compound=paroxetine Accessed 16 August 2012.
Landen 2009 {published data only}
  • Landen M, Erlandsson H, Bengtsson F, Andersch B, Eriksson E. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability. Neuropsychopharmacology 2009;34:585-92.
Miller 2008 {published data only}
  • Miller MN, Newell CL, Miller BE, Frizzell PG, Kayser RA, Ferslew KE. Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study. Journal of Women's Health 2008;17(6):993-7.
Pearlstein 1994 {published data only}
Pearlstein 2000 {published data only}
  • Pearlstein T, Haskett R, Stout A, Frank E, Endicott J. Sertraline improves psychosocial functioning in premenstrual dysphoric disorder. 151st Annual Meeting of the American Psychiatric Association, 30th May- 4th June Toronto, Canada. 1998.
  • Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Journal of Clinical Psychiatry 2000;61(2):101-9.
Rickels 1990 {published data only}
Steiner 1997 {published data only}
  • Steiner M, Korzekwa MI, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacology Bulletin 1997;33:771-4.
Sundblad 1992 {published data only}
Sundblad 1993 {published data only}
  • Sundblad C, Hedberg M, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo controlled trial. Neuropsychopharmacology 1993;9(2):133-45.
Sundblad 1997 {published data only}
  • Sundblad C Wikander I, Andersch B, Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. European Neuropsychopharmacology 1997;7(3):201-6.
Veeninga 1990 {published data only}
Wu 2008 {published data only}
Yonkers 1996 {published data only}
Yonkers 2002 {unpublished data only}
  • Yonkers KA. Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder. http://clinicaltrials.gov/ct2/show/NCT00048854.
Yonkers 2006 {published data only}

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Yonkers 2007 {unpublished data only}
  • Yonkers KA, Altemus M, Kornstein S. Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder. http://www.clinicaltrials.gov/ct2/show/NCT00536198 2007.
Yonkers 2010 {unpublished data only}
  • Yonkers KA. Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS). http://clinicaltrials.gov/ct2/show/NCT00965562 2010.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
ACOG 2000
  • American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG PracticeBulletin No. 15. Washington, DC: ACOG 2000.
APA 2000
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC:American Psychiatric Association; 2000. p. 774. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000:774.
Baker 2012
Cohen 1988a
  • Cohen J. Statistical Power Analysis in the Behavioral Sciences (2nd edition). Statistical Power Analysis in the Behavioral Sciences. 2nd Edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.
Epperson 2012
  • Epperson CN, Steiner M, Hartlage SA, Erikkson E, Schmidt PJ, Jones I, Yonkers KA. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. American Journal of Psychiatry 2012;169(5):465-75.
Ford 2012
Freeman 2009
  • Freeman EW, Rickels K, Sammel MD, Lin H, Sondheimer SS. Time to relapse after short-term or long-term sertraline treatment for severe premenstrual syndromes. Archives of General Psychiatry 2009;66(5):537-44.
Freeman 2012
  • Freeman EW, Sammel MD, Lin H, Rickels K, Sondheimer SJ. Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstetrics and Gynecology 2011;118(6):1293-1300.
Glaxo 2012
  • GlaxoSmithKline Government Affairs, Public Policy, Patient Advocacy. Public Disclosure of Clinical Research. Downloaded from: http://www.google.co.nz/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.gsk.com%2Fpolicies%2FGSK-on-disclosure-of-clinical-trial-information.pdf&ei=lqIIUee4GuTDmQX9hoD4Ag&usg=AFQjCNEcA2G3XGrrh9BkqK1RedmQ53VgQg&bvm=bv.41642243,d.dGY.
Halbreich 2008
  • Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectrum 2008;13(7):566,569-72.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011 ]. Available from www.cochrane-handbook.org.
Ismail 2006
  • Ismail KMK, Crome IB, O'Brien PMS. In: Higham J editor(s). Psychological disorders in obstetrics and gynaecology for the MRCOG and beyond. London: The Royal College of Obstetricicians and Gynaecologists, 2006:37.
Jing 2009
Kleinstauber 2012
  • Kleinstauber M, Witthoft M, Hiller W. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis. Journal of Clinical Psychology in Medical Settings 2012;19:308-19.
Lopez 2012
Magos 1986
Micromedex 2013
  • DRUGDEX® Evaluations. Micromedex.2 database Accessed 2.5.13 via University of Auckland library.
Naheed 2013
  • Naheed B, O'Brien PMS, Uthman OA, O'Mahony F. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010503]
O'Brien 2011
  • O'Brien PMS, Backstrom T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Archives of Womens Mental Health 2011;14:13-21.
Pearlstein 2002
Pearlstein 2007
  • Pearlstein T. Prevalence, impact, on morbidity and burden of disease. In: O’Brien PMS, Rapkin A, Schmidt P editor(s). The premenstrual syndromes: PMS and PMDD. London: Informa Healthcare, 2007:37-47.
Plouffe 1993
  • Plouffe L, Stewart K, Craft KS, Maddox MS, Rausch MD. Diagnostic and treatment results from a south-eastern academic center-based premenstrual syndrome clinic: The first year. Americal Journal of Obstetrics and Gynecology 1993;169(2):295-307.
Rapkin 2008
Shah 2008
  • Shah NJ, Jones JB, Aperi J, Shemtov R, Karne A. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. A meta-analysis. Obstetrics and Gynecology 2008;111(5):1175-82.
Shaw 2003
  • Shaw S, Wyatt K, Campbell J, Ernst E, Thompson-Coon J. Vitex agnus castus for premenstrual syndrome. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004632]
Yu 2005
  • Yu J, Liu B, Liu Z, Welch V, Wu T, Clarke J, Smith CA. Acupuncture for premenstrual syndrome. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005290]

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Dimmock 2000